N/A
Completed N=1,083
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Metastatic Castration Sensitive Prostate Cancer (mCSPC) · Metastatic Castration Resistant Prostate Cancer (mCRPC)
Source: ClinicalTrials.gov NCT05701007 ↗
Enrolled (actual)
1,083
Serious AEs
—
Results posted
Jan 2026
Primary outcomePrimary: Body Mass Index (BMI) — 27.9; 27.1 Kilogram per meter square
Summary
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions:
* What are the demographic and clinical characteristics of metastatic prostate cancer patients?
* How are metastatic prostate cancer patients currently treated and how effective are these treatments?
* How does the development of castration-resistance affect patient outcomes?
* What is the economic burden of metastatic prostate cancer?
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Body Mass Index (BMI) |
27.9; 27.1 | — |
| PRIMARY Prostate-Specific Antigen (PSA) |
199.7; 92 | — |
| PRIMARY Alkaline Phosphatase (P-AFOS) |
214.1; 144 | — |
| PRIMARY Length of Follow-up |
1.8; 1.9 | — |
| PRIMARY Number of Participants With de Novo Metastasis |
444; 240 | — |
| PRIMARY Number of Participants Who Received Treatment for mCRPC and mCSPC |
668; 536 | — |
| PRIMARY Number of Participants Diagnosed With mCSPC Who Progressed to mCRPC |
270 | — |
| PRIMARY Number of Participants With Orchiectomy |
10; 9 | — |
| PRIMARY Number of Participants Undergone Palliative Radiology |
222; 187 | — |
| PRIMARY Number of Participants With Symptomatic Skeletal-Related Event (SSRE) |
44; 43 | — |
| PRIMARY Number of Participants With Osteoporosis |
9; NA | — |
| PRIMARY Number of Participants Who Were on Bone Medication |
154; 292 | — |
| PRIMARY Number of Participants Who Were on Opioids |
310; 332 | — |
| PRIMARY Number of Participants Classified Per Charlson Comorbidity Index (CCI) Scores |
548; 329; 147; 142; 61; 52 | — |
| PRIMARY Number of Participants Classified Per Gleason Score |
7; 12; 46; 31; 171; 88 | — |
| PRIMARY Number of Participants Based on Tumor Node Metastasis (TNM) Classification: T |
13; 0; 0; 12; 28; 0 | — |
| PRIMARY Number of Participants Based on Tumor Node Metastasis (TNM) Classification: N |
41; 17; 65; 0; 0; 25 | — |
| PRIMARY Number of Participants Based on Tumor Node Metastasis (TNM) Classification: M |
50; 29; 113; 36 | — |
| PRIMARY Number of Participants Based on Eastern Cooperative Oncology Group Performance Status (ECOG PS) |
175; 97; 181; 112; 64; 67 | — |
| PRIMARY Number of Participants According to Treatment Per Treatment Line for mPC: mCSPC Participants |
60; 8; 60; 244; 39; 22 | — |
| PRIMARY Number of Participants According to Treatment Per Treatment Line for mPC: mCRPC Participants |
23; 77; 5; 59; 23; 55 | — |
| PRIMARY Overall Survival (OS) |
52.6; 27.6; 12.2; 4.2 | — |
| PRIMARY Time to Next Treatment (TTNT) |
9.9; 10.3; 33.1; 6.6; NA; 4.0 | — |
| PRIMARY Time to Disease Progression |
19.4 | — |
| PRIMARY Number of Participants Per Factors Associated With Disease Progression to Castration Resistant |
101; 45; 111; 186; 42; 29 | — |
| PRIMARY Annual Incidence of mPC, mCSPC and mCRPC |
16.81; 10.48; 5.73; 2.57; 2.97; 18.09 | — |
| PRIMARY Number of Events Per Participant Year for Outpatient Clinic Contacts, Hospitalization Contacts |
14.2; 18.6; 0.7; 1.2 | — |
| PRIMARY Number of Days Per Participant Year for Hospital Inpatient Days |
3.1; 6.5 | — |
Eligibility Criteria
Inclusion Criteria
- Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022
- Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
- Detection of metastatic prostate cancer
Exclusion Criteria
- Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014
- Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
Data sourced from ClinicalTrials.gov (NCT05701007). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.